Home / Peptides / Cagrilintide
Cagrilintide (CagriSema) Dosage Chart and Schedule
Not approved
Long-acting amylin analogue from Novo Nordisk, paired with semaglutide as CagriSema. Not approved yet.
Also called: NN9838, CagriSema
Regulatory status (US)
Not approved. Novo Nordisk filed CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg weekly) with the FDA in December 2025 and expects a decision in late 2026; as of November 15, 2026 it was still not approved. Cagrilintide on its own is investigational and is not on any compounding list.
What it is
A long-acting, once-weekly analogue of amylin, a hormone released with insulin that slows stomach emptying and increases fullness.
Doses studied
| Trial | Weekly dose | Result |
|---|---|---|
| Phase 2, cagrilintide alone | 0.3 to 4.5 mg | 6.0% to 10.8% weight loss at 26 weeks |
| REDEFINE 1, CagriSema | 2.4 mg cagrilintide + 2.4 mg semaglutide | 20.4% at 68 weeks |
Trial doses, not a label or a recommendation. The escalation schedule used in REDEFINE 1 is not shown here because we could not confirm it.
Cagrilintide reconstitution calculator
Enter your vial and your prescribed dose to see the units on a U-100 syringe.
What human studies show
- Phase 2 (Lancet 2021, 706 adults, 26 weeks): weekly 0.3, 0.6, 1.2, 2.4 or 4.5 mg. Weight loss ranged from 6.0% to 10.8% at 4.5 mg, vs 3.0% on placebo.
- REDEFINE 1 (NEJM 2025, 3,417 adults, 68 weeks): CagriSema 2.4 mg + 2.4 mg weekly gave 20.4% average weight loss vs 3.0% on placebo.
Safety
- No FDA label. Trial side effects were mainly gastrointestinal.
Compare
Questions
- Is Cagrilintide FDA-approved?
- Not approved. Novo Nordisk filed CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg weekly) with the FDA in December 2025 and expects a decision in late 2026; as of November 15, 2026 it was still not approved. Cagrilintide on its own is investigational and is not on any compounding list.
- What dose of Cagrilintide has been studied?
- Phase 2, cagrilintide alone: 0.3 to 4.5 mg: 6.0% to 10.8% weight loss at 26 weeks; REDEFINE 1, CagriSema: 2.4 mg cagrilintide + 2.4 mg semaglutide: 20.4% at 68 weeks. Trial doses, not a label or a recommendation. The escalation schedule used in REDEFINE 1 is not shown here because we could not confirm it.
- How many units is my Cagrilintide dose?
- Divide the mg in the vial by the mL of bacteriostatic water to get mg/mL, divide your dose in mg by that, and multiply by 100 for units on a U-100 syringe. The calculator on this page does it and draws the syringe.
Related
Sources
- Lau et al. Once-weekly cagrilintide for weight management: phase 2 trial. Lancet 2021
- Garvey et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). NEJM 2025
- Novo Nordisk company announcement on CagriSema (Nov 2026)
- FDA 510(k) K212499: BD insulin syringes for U-100 insulin
Last checked 2026-11-16. How we pick and check sources: methodology.